Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery

• Status: Withdrawn
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study will be to determine whether secretin-enhanced MRCP (S-MRCP) as well as traditional magnetic resonance imaging (MRI) of the pancreas will allow the investigators to quantify the pancreas' ability to secrete hormones as well as digestive enzymes, both before and after surgery. The investigators hypothesize that S-MRCP will provide a novel non-invasive measure of pancreatic function.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Columbia University
• Treatments: Secretin

Criteria

Inclusion Criteria:

• 18 years of age and older.

• Tissue-confirmed diagnosis of pancreatic adenocarcinoma.

• Scheduled for surgical resection of the adenocarcinoma (Whipple or distal pancreatectomy).

• Able to give informed consent

Exclusion Criteria:

• History of any radiation therapy to the abdomen prior to surgery.

• Any contraindication to MRI, including but not limited to implanted metal devices (e.g. pacemaker, berry aneurysm clips, neural stimulator, cochlear implants, or metal in the eye).

• Treatment with an investigational drug within 1 month prior to the day of the study drug administration.

• Current enrollment in any other interventional study.

• Creatinine greater than 2.0.

• Significant liver disease, liver masses, or evidence of portal hypertension.

• Pregnancy.

• History of sensitivity to secretin.

• Unwilling or unable to sign informed consent.